This lack of diversity in trials to test targeted therapies has important implications for breast cancer disparities given the marked variation in the prevalence of certain mutations of high-penetrance genes, such as BRCA1 and BRCA2 [13], and breast tumor subtypes across racial and ethnic populations [14–16]. The gene discussed is BRCA1; the disease is breast cancer.